The poor prognosis in the subgroup of patients with RHAMM+/TIL− tumours is independent of pT or pN stage suggesting that this multimarker phenotype could be helpful in selecting patients for adjuvant chemotherapy. The gene discussed is HMMR; the disease is neoplasm.